Trials evaluating the single-agent Isatuximab, a CD38 monoclonal antibody (MoAb), in patients with relapsed/refractory amyloid light-chain (AL) amyloidosis. https://ashpublications.org/blood/article/146/21/2495/548147/Isatuximab-surface-strike-deep-response-in-AL